Cilostazol Capsules
Function and Efficacy
The mechanism of action of this product in improving intermittent thromboembolism symptoms is not yet fully understood. This product and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors (PDEIII inhibitors), which can reduce the degradation of cAMP by inhibiting the activity of phosphodiesterase, thereby increasing the cAMP level in platelets and blood vessels, inhibiting platelet aggregation and vasodilation.
Ingredients
6-[4-(1-cyclohexyl-1H-pentyletetrazolium (5'))butoxy]-3,4-dihydro-1H-quinolone (2)
Appearance
The content of this product is white granular powder.
Indication
Improve symptoms such as chronic ulcers, pain, chills and intermittent claudication caused by chronic arteriosclerosis obliterans.
Usage and Dosage
Oral administration: 100 mg (two capsules) at a time, twice a day. The dosage can be increased or decreased according to the condition.
Adverse Reactions
1 Systemic adverse reactions: abdominal pain, back pain, headache, infection, edema. 2 Circulatory system: occasional palpitations, rapid pulse, fever, dizziness, hypotension. 3 Digestive system: occasional stomach discomfort, upper abdominal pain, abdominal distension, loss of appetite, nausea, vomiting, soft stools, diarrhea. 4 Allergic reactions: occasional rash, eruptions, urticaria, itching. 5 Nervous system: occasional headache, heavy head, dizziness, vertigo, insomnia, numbness, occasional drowsiness, fatigue. 6 Liver: occasional increase in AST, ALT, LDH values. 7 Kidney: occasional increase in BUN, creatine, uric acid values
Precautions
1. Patients who are allergic to any component of this drug. 2. Patients with grade 3-4 congestive heart failure. 3. Patients with bleeding such as hemophilia, capillary fragility, upper gastrointestinal bleeding, hemoptysis, etc. 4. Women who are pregnant or may become pregnant.
Special Population Medication
Pregnancy and lactation precautions: Women who are pregnant or may become pregnant.
Drug Interactions
Prostaglandin E1 works synergistically with this product to increase intracellular cyclic guanosine-phosphate and enhance therapeutic efficacy.
Storage
Store in a sealed container at room temperature. The validity period is tentatively set at two years.
Packaging Specification
50mg
Manufacturer
Chongqing Pharscin Pharmaceutical Co., Ltd.
-
Founded in:
1996-11-04 -
Address:
Chongqing Rongchang District Industrial Park -
Tax NO.:
915002262038944463 -
Registered Funds:
417.596314 million yuan -
Website:
-
Email: